When alcohol meets Alzheimer’s: New study reveals an unexpected interaction in the brain
Peer-Reviewed Publication
In honor of Alzheimer's Awareness Month, we’re exploring the science and stories surrounding Alzheimer’s disease.
Updates every hour. Last Updated: 28-Oct-2026 11:16 ET (28-Oct-2026 15:16 GMT/UTC)
The team studied a brain circuit called the corticostriatal circuit, which helps control decision-making and behavioral flexibility. When this circuit does not work properly, people may struggle to adapt to new information or changing environments.
A molecular imaging technology developed by Prof. Shai Rahimipour of Bar-Ilan University is helping scientists uncover one of the earliest and most elusive drivers of Alzheimer's disease, opening new possibilities for earlier diagnosis and more precise treatment.
The technology played a central role in a new international study published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, led by researchers at the Icahn School of Medicine at Mount Sinai in New York together with collaborators from Bar-Ilan University and Canada. The study provides compelling evidence that soluble amyloid-beta oligomers -- tiny toxic protein aggregates believed to trigger Alzheimer's disease years before symptoms appear -- can damage brain cells long before they become detectable by today's diagnostic methods.
A molecule linked to chronic inflammation disrupts the brain’s ability to create new neurons – uncovering a pathway with therapeutic potential for neurodegenerative diseases and neurological conditions.